Vosoritide: How a C-Type Natriuretic Peptide Drug Affects Growth in Achondroplasia

Table of Contents

1. What Vosoritide Is
2. How It Pushes Back Against the Overactive Growth Brake
3. The First Trial in Children: Finding the Dose
4. The Phase 3 Trial and the Label's Growth Figures
5. What Happened When Children Kept Taking It
6. The Trial in Babies and Children Under Five
7. Side Effects Reported in the Label
8. Who the Label Covers and How the Dose Is Set
9. What Is Not Yet Known
10. Related Drugs Aimed at the Same Pathway
11. Key Research Papers
12. Connections
13. Featured Videos

What Vosoritide Is

Vosoritide is a laboratory-made copy of a natural body signal called C-type natriuretic peptide (CNP). The body makes C-type natriuretic peptide in many tissues, and one of its jobs is to tell the cartilage cells inside a child's growth plates to multiply and mature. The growth plates are the soft bands of cartilage near the ends of the long bones where a bone gets longer during childhood. The 2019 phase 2 trial report describes C-type natriuretic peptide as "a potent stimulator of endochondral ossification" — the process by which that cartilage is turned into new bone.

The natural signal does not last long in the blood because an enzyme called neutral endopeptidase breaks it down. According to the label, vosoritide is a chain of 39 amino acids: the last 37 amino acids of the human C-type natriuretic peptide sequence, plus two extra amino acids (proline and glycine) added to the front end to make the molecule resistant to that enzyme. It is made by bacteria (Escherichia coli) using recombinant DNA technology and is supplied as a powder that is mixed with sterile water before each injection.

Even with that change, the drug leaves the blood quickly. The label reports that it reaches its highest level about 15 minutes after the injection and that its mean half-life (the time for half of it to be cleared) ranged from 21.0 to 27.9 minutes in children. A daily injection is therefore needed. The label also reports that the drug's effect on the growth plate can be traced in the body: a marker of the cartilage-to-bone process, serum collagen type X marker, rose with daily treatment and stayed raised beyond 24 months.

Back to Table of Contents

How It Pushes Back Against the Overactive Growth Brake

In achondroplasia, a single change in the gene for fibroblast growth factor receptor 3 (FGFR3) leaves that receptor switched on too much of the time. In a healthy growth plate, the receptor works as a brake: it slows the cartilage cells down so that growth stays in step with the rest of the body. With the receptor overactive, the brake is pressed too hard, the cartilage cells multiply and mature less than in a typical growth plate, and the long bones stay short. The Achondroplasia page explains the genetics in detail.

Vosoritide does not touch the faulty receptor itself. Instead, it works through a second, separate signal inside the same cartilage cells. The label describes the chain of events this way:

• Vosoritide attaches to natriuretic peptide receptor B on the surface of the cartilage cell.
• That receptor raises the level of a messenger molecule inside the cell, cyclic guanosine monophosphate. The label reports that levels of this messenger in the urine of treated children rose within four hours of an injection and peaked at about two hours.
• The rise interrupts the main growth-slowing route that the overactive receptor uses, the mitogen-activated protein kinase pathway, at a step called RAF-1, which reduces the activity of the downstream enzymes ERK1 and ERK2.
• With that route damped, the cartilage cells multiply and mature more, so the drug acts, in the label's words, "as a positive regulator of endochondral bone growth."

In other words, the faulty receptor keeps pressing its brake, and vosoritide eases the pressure further down the same line. The label adds that in animal models with open growth plates, the drug widened the growth plate and increased skeletal growth, and that in mice bred to carry receptor changes of this kind, the short-limbed body shape was partly or completely normalized. Those results were seen in animals; the human results are described in the trial sections below.

Because the drug acts through the cartilage of open growth plates, it has nothing to work on once the growth plates have closed at the end of puberty. That is why the label limits use to children whose growth plates are still open.

Back to Table of Contents

The First Trial in Children: Finding the Dose

The first study in children with achondroplasia, published in 2019, was a phase 2 dose-finding study with a long-term extension. Its purpose was to see how the drug was tolerated and which dose worked.

• Who took part: 35 children aged 5 to 14 years, enrolled in four groups one after another.
• Doses tested: 2.5, 7.5, 15.0 or 30.0 micrograms per kilogram of body weight, injected under the skin once a day. After 6 months, the two lowest-dose groups were stepped up toward 15.0 micrograms per kilogram.
• Length of follow-up: a median of 42 months across the dose-finding study and its extension.
• Growth: during the first 6 months, growth speed rose with the dose up to 15.0 micrograms per kilogram. At 15.0 and 30.0 micrograms per kilogram, the increase in growth speed was sustained for up to 42 months. The phase 3 trial that followed used 15.0 micrograms per kilogram.
• Side effects: every child (35 of 35) had at least one adverse event of some kind, and 4 of 35 (11%) had a serious adverse event. Treatment was stopped in 6 children, in 1 of them because of an adverse event. The authors described the side-effect profile as "generally mild."

A phase 2 study of this kind has no placebo group, so it can show a dose pattern and early safety but cannot prove how much of the growth came from the drug. That question went to the phase 3 trial.

Back to Table of Contents

The Phase 3 Trial and the Label's Growth Figures

The phase 3 trial, published in The Lancet in 2020, compared vosoritide with a placebo injection (a dummy injection with no drug) for 52 weeks. It ran at 24 hospitals in seven countries: Australia, Germany, Japan, Spain, Turkey, the United States and the United Kingdom. Neither the families nor the doctors knew which children received the drug.

• Who took part: 121 children with achondroplasia, 60 given vosoritide and 61 given placebo. The label reports their ages as 5.1 to 14.9 years, with a mean of 8.7 years. Each child's growth had first been measured for at least 6 months in a baseline study, so that every child's own starting growth speed was known.
• How tall the children were at the start: the label reports a mean height standard deviation score of −5.13, meaning the average child was a little more than five standard deviations below the average height for children of the same age and sex in the general population.
• The dose: 15.0 micrograms per kilogram once a day, injected at home by trained caregivers.

The main measure was annualized growth velocity — how many centimeters a child grows per year. The label's Table 5 gives the figures (61 children on placebo, 60 on vosoritide):

• Starting growth speed (mean): 4.06 cm per year on placebo; 4.26 cm per year on vosoritide.
• Change after 52 weeks: −0.17 cm per year on placebo; +1.40 cm per year on vosoritide.
• Difference between the groups: 1.57 cm per year in favor of vosoritide (95% confidence interval 1.22 to 1.93; p<0.0001).

In plain terms, children on placebo grew at about the same speed as before, while children on vosoritide grew about 1.4 cm per year faster than they had been growing. The label states that the improvement was consistent across every predefined subgroup it analyzed, including sex, age group, stage of puberty, starting height and starting growth speed.

The label also reports two further measures from the same trial:

• Height score: the height standard deviation score moved by 0.26 in the vosoritide group and by −0.02 in the placebo group, a difference of 0.28 (95% confidence interval 0.17 to 0.39). The children on the drug moved slightly closer to the general-population average for their age.
• Body proportions: the upper-to-lower body segment ratio, a measure of how long the trunk is compared with the legs, changed by −0.03 with vosoritide and −0.02 with placebo. The difference, −0.01, was not statistically significant (p=0.5). Over one year, the trial did not show a change in body proportions.

The trial authors' own interpretation in the Lancet summary was that vosoritide increased growth in children with achondroplasia, and that "it is not known whether final adult height will be increased, or what the harms of long-term therapy might be." In the same trial, 59 of 60 children on vosoritide (98%) and 60 of 61 on placebo (98%) had at least one adverse event; none of the serious adverse events were judged to be caused by the treatment, and no child died.

Back to Table of Contents

What Happened When Children Kept Taking It

After the 52-week trial, children could move into an open-label extension, where everyone received vosoritide and everyone knew it. The results of an open-label extension are useful for seeing whether an effect lasts, but they lack a placebo group, so comparisons rely on outside reference data.

• Two years: the 2021 report of the extension found that in children first assigned to vosoritide, growth speed rose from 4.26 cm per year at the start to 5.39 cm per year at 52 weeks and 5.52 cm per year at 104 weeks. In children who switched from placebo to vosoritide, growth speed rose from 3.81 cm per year at week 52 to 5.43 cm per year at week 104. No new adverse effects were found. The label itself states only that among children with two years of follow-up, the improvement in growth speed was maintained.
• Up to six years: a 2025 report on 119 participants compared treated children with untreated children with achondroplasia from a separate natural-history study. The mean difference in yearly growth speed between treated and untreated children, across each year of age from 6 to 16, was 1.84 cm per year in boys and 1.44 cm per year in girls. Over three years, treated children had gained an estimated 5.75 cm more height than the untreated comparison group (95% confidence interval 4.93 to 6.57). The authors reported no long-term harms or deaths across 464.05 person-years of treatment.
• Body proportions over three years: the same 2025 report found a statistically significant improvement in the upper-to-lower body segment ratio after three years of treatment, but only in the subgroup assessed before age 11 in girls and before age 12 in boys, compared with untreated children of the same age. The ratio of arm span to standing height stayed in line with untreated children.
• Complications: a 2026 analysis pooled six vosoritide trials, covering 230 children by August 2024, and compared the rate of achondroplasia complications with published natural-history rates. New or worsening leg bowing, narrowing at the base of the skull (foramen magnum stenosis), spinal stenosis, spinal curvature, fluid build-up in the brain, ear, nose and throat problems and pain were generally less common than in the natural-history reports. Surgery to widen the foramen magnum was performed in 3.0% of children overall and in 5.9% of those who began treatment before age 2. The authors concluded that vosoritide "was not associated with worsening of complications" and "may reduce their frequency."

These longer-term comparisons set treated children against historical or external groups rather than against children randomly assigned to placebo, and the studies were funded by the drug's maker. Both points limit how firmly the size of the effect can be stated.

Back to Table of Contents

The Trial in Babies and Children Under Five

Because the growth plates are most active early in life, a second placebo-controlled trial tested vosoritide in younger children. Its results were published in 2024.

• Who took part: 75 children younger than 60 months, in three age groups: 24 to 59 months, 6 to 23 months, and 0 to 5 months. Achondroplasia was confirmed by genetic testing in every child. Of the 75, 11 received the drug openly to set the dose, 32 were randomly assigned to vosoritide and 32 to placebo.
• Doses given: the trial gave 30.0 micrograms per kilogram a day to infants aged 0 to 23 months and 15.0 micrograms per kilogram a day to children aged 24 to 59 months, for 52 weeks.
• Height result: the difference in the change in height score between the vosoritide and placebo groups was 0.25, with a 95% confidence interval of −0.02 to 0.53. Because that range crosses zero, the result falls short of the usual threshold for a clear difference.
• Side effects: all 75 children had at least one adverse event. The yearly rate was 204.5 adverse events per child in the vosoritide group and 73.6 per child in the placebo group, mostly short-lived injection-site reactions and skin redness at the injection site.
• Serious events: serious adverse events occurred in 3 children (7%) in the vosoritide group — low oxygen levels; a respiratory syncytial virus chest infection (bronchiolitis) together with sudden infant death syndrome; and pneumonia — and in 6 children (19%) in the placebo group. One child in the vosoritide group died, and one child in the placebo group withdrew.

The label's summary of this trial states that the most common adverse reactions in children under 5 were injection-site reactions (86%) and rash (28%), and that the overall safety profile was similar to that in older children.

Back to Table of Contents

Side Effects Reported in the Label

The label's Table 3 lists the adverse reactions that occurred in at least 5% of children on vosoritide in the phase 3 trial and more often than on placebo (60 children on vosoritide, 61 on placebo):

• Injection-site redness: 45 (75%) on vosoritide; 42 (69%) on placebo.
• Injection-site swelling: 37 (62%) on vosoritide; 22 (36%) on placebo.
• Vomiting: 16 (27%) on vosoritide; 12 (20%) on placebo.
• Injection-site hives: 15 (25%) on vosoritide; 6 (10%) on placebo.
• Joint pain: 9 (15%) on vosoritide; 4 (7%) on placebo.
• Decreased blood pressure: 8 (13%) on vosoritide; 3 (5%) on placebo.
• Gastroenteritis (stomach and bowel infection): 8 (13%) on vosoritide; 5 (8%) on placebo.
• Diarrhea: 6 (10%) on vosoritide; 2 (3%) on placebo.
• Dizziness: 6 (10%) on vosoritide; 2 (3%) on placebo.
• Ear pain: 6 (10%) on vosoritide; 3 (5%) on placebo.
• Influenza: 6 (10%) on vosoritide; 3 (5%) on placebo.
• Tiredness: 5 (8%) on vosoritide; 2 (3%) on placebo.
• Seasonal allergy: 4 (7%) on vosoritide; 1 (2%) on placebo.
• Dry skin: 3 (5%) on vosoritide; 0 on placebo.

Injection-site reactions

Injection-site reactions were common in both groups, because both groups had a daily injection: 51 of 60 children (85%) on vosoritide and 50 of 61 (82%) on placebo. The difference showed in how often they happened. Over 52 weeks, the vosoritide group had 6,983 injection-site reaction events and the placebo group 1,776, which the label gives as 120.4 events per person-year versus 29.2. Two children on vosoritide stopped treatment because of pain and anxiety with the injections.

Low blood pressure

The label's only warning is a risk of low blood pressure. The label reports that 8 of 60 children on vosoritide (13%) had a total of 11 episodes of a short-lived drop in blood pressure, compared with 3 of 61 (5%) on placebo. Most were picked up during close monitoring at clinic visits after a dose. The median time to onset was 31 minutes after the injection (range 18 to 120), and the drop resolved within a median of 31 minutes (range 5 to 90). Two of the 60 children on vosoritide (3%) each had one episode with symptoms — vomiting and/or dizziness — compared with none on placebo. The label lists dizziness, fatigue and nausea as the symptoms linked to a drop in blood pressure. It instructs that the child eat adequately and drink about 240 to 300 mL of fluid in the hour before each injection to reduce that risk. Children with significant heart or blood-vessel disease, and children taking blood-pressure-lowering medicines, were excluded from the trials, so the label has no trial data on them.

Other findings in the label

• Alkaline phosphatase: more children on vosoritide had a rise in this blood enzyme, which is also a marker of bone growth (17% versus 7% on placebo).
• Antibodies to the drug: 35% of children aged 5 and older (46 of 131) and 33% of children under 5 (20 of 61) developed antibodies against vosoritide. None of these antibodies blocked the drug, and the label reports no link between them and growth, injection-site reactions or allergy-type reactions.
• Reports after approval: excess hair growth (hypertrichosis) has been reported during use after approval. Because such reports are voluntary, the label notes that their frequency and cause cannot be reliably established.
• Kidneys: the label states that vosoritide is not recommended for people with an estimated glomerular filtration rate (a measure of kidney function) below 60 mL/min/1.73 m²; the effect of reduced kidney function on the drug has not been studied.
• Heart rhythm: at the maximum approved dose, the label reports no clinically relevant lengthening of the QT interval, a heart-rhythm measure.
• Pregnancy and breastfeeding: there are no human data. In pregnant rats and rabbits, doses giving 14 and 200 times the human exposure caused no birth defects or harm to the developing young. The drug is present in rat milk; whether it passes into human milk is unknown.
• Contraindications: the label lists none.

Back to Table of Contents

Who the Label Covers and How the Dose Is Set

The current United States label (revised November 2025) states that vosoritide is "indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses." Epiphyses are the growth plates. The indication names no lower age limit: the label's dosing table starts at a body weight of 3 kg, and the label's pediatric-use section cites drug-level data in children from 4.5 months to 15 years and safety data from 4.4 months. Some descriptions give age 5 as the lower limit; the current label’s indication covers children of any age whose growth plates are open.

The label also states that this is an accelerated approval. The United States Food and Drug Administration (FDA) granted it on the basis of an improvement in growth speed, and "continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s)." In other words, growth speed was accepted as an early measure, and further trials are expected to show the benefit that matters to families.

How the dose works

• The dose is set by the child's actual body weight and given as one injection under the skin each day, at about the same time if possible.
• The label's weight table runs from 0.096 mg a day at 3 kg to 0.8 mg a day at 90 kg or more. The phase 3 trial gave 15 micrograms per kilogram a day.
• Injection sites listed are the front of the middle thighs, the lower abdomen at least 5 cm (2 inches) from the navel, the top of the buttocks and the back of the upper arms, with the same area not used on two days in a row.
• A missed dose can be given within 12 hours; after that, the label says it is skipped.
• The label calls for weight, growth and development to be checked every 3 to 6 months, with the dose adjusted to body weight, and for treatment to be stopped permanently once the growth plates have closed.
• Caregivers may give the injection after training by a health professional.

Decisions about starting, continuing or stopping a medicine belong with the child's clinicians and family.

Back to Table of Contents

What Is Not Yet Known

The trials show that vosoritide makes children with achondroplasia grow faster while they take it. Several larger questions are still open in the published research:

• Adult height. No trial has yet followed treated children to their final adult height. The phase 3 authors wrote that "it is not known whether final adult height will be increased." The three-year gain of about 5.75 cm comes from comparison with an outside untreated group, not from a placebo-controlled trial running to adulthood.
• Body proportions. The one-year placebo-controlled trial found no change in the upper-to-lower body segment ratio (difference −0.01, p=0.5). A 2026 meta-analysis that pooled four randomized trials of C-type natriuretic peptide drugs likewise found no short-term effect on that ratio. The three-year extension found an improvement only in children assessed before age 11 to 12, and the arm span-to-height ratio did not change. Whether the drug changes the short-limb proportions of achondroplasia over a full childhood is not settled.
• Complications. The pooled analysis of six trials suggests that complications such as foramen magnum stenosis, spinal stenosis and leg bowing were not made worse and may be less frequent. Because the comparison is with historical natural-history rates rather than a randomized control group, the authors' wording is that vosoritide "may reduce" their frequency.
• Long-term harms. The phase 3 authors listed the harms of long-term therapy as unknown. The six-year extension reported no long-term harms across 464.05 person-years, and the label notes that long-term cancer-risk and genetic-damage studies of vosoritide have not been performed.
• The size of the effect. A 2026 meta-analysis of C-type natriuretic peptide drugs described the gain in linear growth as "slight but statistically meaningful," with a pooled increase in growth speed of 1.36 cm per year and in standing height of 1.24 cm, and concluded that long-term studies are needed to define the best timing of treatment for adult height, physical function and complications. A second 2026 systematic review of vosoritide reached a similar conclusion, calling for longer studies that run until puberty.

Achondroplasia does not affect intelligence, and many adults with the condition, and organizations of people of short stature, regard height as only one part of the picture. The open questions above are about medical outcomes; how families weigh them is a separate, personal matter.

Back to Table of Contents

Related Drugs Aimed at the Same Pathway

Vosoritide opened the way for other drugs that work on the overactive growth-brake pathway, each from a different angle.

Navepegritide — a once-weekly C-type natriuretic peptide drug, now approved

Navepegritide is a prodrug (an inactive form that the body slowly converts into the active drug) that releases C-type natriuretic peptide steadily over a week, so it is injected once weekly instead of daily. In the APPROACH trial, 84 children aged 2 to 11 years were randomly assigned in a 2-to-1 ratio to navepegritide (100 micrograms per kilogram per week) or placebo for 52 weeks. Growth speed was 1.49 cm per year higher with navepegritide than with placebo (95% confidence interval 1.05 to 1.93). The trial also reported improvements in leg alignment and in a physical-functioning score in children younger than 5 years. Injection-site reaction rates were low, and no low blood pressure with symptoms was observed. Its United States label, first approved in 2026, covers children 2 years of age and older with achondroplasia and open growth plates, also under accelerated approval.

Infigratinib — a tablet that blocks the receptor directly, in trials

Infigratinib works differently: it is a small molecule taken by mouth that blocks the overactive receptor itself (and its two close relatives, fibroblast growth factor receptors 1 and 2). In the 2025 phase 2 dose-finding study of 72 children aged 3 to 11 years, the highest-dose group (0.25 mg per kilogram a day) showed a mean increase in growth speed of 2.50 cm per year at 18 months compared with the children's own starting values, along with a change in the upper-to-lower body segment ratio of −0.12; this study had no placebo group. The 2026 phase 3 trial then randomly assigned 114 children aged 3 to 17 years to infigratinib or placebo for 52 weeks. Growth speed was 1.74 cm per year higher with infigratinib (95% confidence interval 1.31 to 2.17), and the height score difference was 0.32. The difference in the upper-to-lower body segment ratio, −0.02, did not reach statistical significance. Serious adverse events occurred in 4 of 74 children (5%) on infigratinib and 1 of 39 (3%) on placebo, and none was judged related to the treatment.

Recifercept — development stopped

Recifercept was designed as a decoy: a soluble copy of the receptor meant to soak up the growth factors that switch the real receptor on. In its phase 2 study in children aged 2 to 10 years, there was no placebo group. Instead, researchers built a model of how each child would have grown without treatment from natural-history data, and compared it with the measured growth. For every dose tested, the measured standing height, sitting height and arm span at 6 and 12 months were comparable to the predicted untreated values, "suggesting no treatment effect." The authors reported that these results contributed to the decision to end recifercept's clinical development.

The two C-type natriuretic peptide drugs together

The 2026 meta-analysis that pooled the randomized trials of vosoritide and navepegritide (4 trials, 326 children) found overall and serious adverse-event rates comparable to placebo, with higher relative risks for injection-site reactions (1.65), hives (4.04) and swelling (3.57). Growth speed rose by a pooled 1.36 cm per year, with no short-term effect on body proportions.

Back to Table of Contents

Key Research Papers

1. Savarirayan R, Irving M, Bacino CA, et al. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. N Engl J Med. 2019;381(1):25-35. PubMed PMID: 31269546
2. Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020;396(10252):684-692. PubMed PMID: 32891212
3. Savarirayan R, Tofts L, Irving M, et al. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet Med. 2021;23(12):2443-2447. PubMed PMID: 34341520
4. Savarirayan R, Wilcox WR, Harmatz P, et al. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Child Adolesc Health. 2024;8(1):40-50. PubMed PMID: 37984383
5. Savarirayan R, Irving M, Wilcox WR, et al. Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study. Med. 2025;6(5):100566. PubMed PMID: 39740666
6. Savarirayan R, Hecht JT, Jayaram K, et al. Evaluating the impact of vosoritide on complications of achondroplasia. Genet Med. 2026;28(7):102584. PubMed PMID: 42001280
7. Kamrul-Hasan ABM, Uday S, Nagendra L, et al. Achondroplasia management in the era of targeted therapies: a meta-analysis of C-type natriuretic peptide analogs. J Endocr Soc. 2026;10(7):bvag121. PubMed PMID: 42306228
8. Pahuja M, Prakash C, Umrao A, et al. Efficacy and safety of Vosoritide in achondroplasia: A systematic review and meta-analysis. Indian J Med Res. 2026;163(1):78-87. PubMed PMID: 41934413
9. Savarirayan R, McDonnell C, Bacino CA, et al. Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial. JAMA Pediatr. 2026;180(1):18-25. PubMed PMID: 41247754
10. Savarirayan R, De Bergua JM, Arundel P, et al. Oral Infigratinib Therapy in Children with Achondroplasia. N Engl J Med. 2025;392(9):865-874. PubMed PMID: 39555818
11. Savarirayan R, Hoover-Fong J, Irving M, et al. Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia. N Engl J Med. 2026;395(9):859-869. PubMed PMID: 42370681
12. Qiao W, Boucher M, Slade A, et al. Natural disease course modeling of achondroplasia to evaluate the efficacy of recifercept in the absence of a placebo control arm in phase II study. CPT Pharmacometrics Syst Pharmacol. 2024;13(7):1103-1116. PubMed PMID: 38685585
13. United States prescribing information for vosoritide for injection, revised November 2025. DailyMed, U.S. National Library of Medicine. DailyMed setid 228e8560-04a4-4bb1-a81f-29531a9e4d27
14. United States prescribing information for navepegritide, first approved 2026. DailyMed, U.S. National Library of Medicine. DailyMed setid e01c1197-338f-414c-b804-808e129ebc8c

PubMed Topic Searches

1. PubMed: vosoritide and achondroplasia
2. PubMed: vosoritide extension studies
3. PubMed: C-type natriuretic peptide and the growth plate
4. PubMed: navepegritide and infigratinib in achondroplasia

Back to Table of Contents

Connections

• Drugs — every drug page on the site
• Achondroplasia — the condition this drug treats
• Genetics — the genetic conditions section
• Growth Hormone: How You Grow — an animation of how children grow and why it stops
• IGF-1 Test — the growth-factor blood test
• BNP and NT-proBNP — the heart's natriuretic peptides, relatives of C-type natriuretic peptide
• Spinal Stenosis — a common complication of achondroplasia in adults
• Osteogenesis Imperfecta — another genetic bone condition

Back to Table of Contents

Featured Videos